Program
BTK Inhibitor TQB3702
Also written as “TQB3702 tablets” and “TQB3702 Tablets”.
In Sino Biopharmaceutical’s pipeline, BTK抑制剂
. Its studies are mostly in Lupus Erythematosus, Systemic · Hematologic Neoplasms, led by Sino Biopharmaceutical.
Furthest: phase 2, since Feb 27, 20254 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 43 open or running | phase 2since Feb 27, 2025 | Nov 2, 2022 | Dec 2026phase 2 · NCT06859931 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 2, 2022First study: phase 1 study in Hematologic NeoplasmsFirst studyNCT05610202 · 137 enrolled · China
- Jan 9, 2024Phase 1 study in Hematologic NeoplasmsNCT06211751 · 208 planned · China
- Jun 4, 2024Phase 1 study in Lupus Erythematosus, SystemicNCT06448273 · 40 planned · China
- Feb 27, 2025Phase 2 study in Lupus Erythematosus, SystemicNCT06859931 · 120 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT06859931
TargetBeta
“BTK抑制剂”the company's pipeline, read by Claude · source
“An orally bioavailable inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), ”NCIt, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06859931Lupus Erythematosus, Systemic · China | 2 | Not yet recruiting | Dec 2026 | 120 |
| NCT06448273Lupus Erythematosus, Systemic · China | 1 | Recruiting | Oct 2024 | 40 |
| NCT06211751Hematologic Neoplasms · China | 1 | Not yet recruiting | Dec 2025 | 208 |
| NCT05610202Hematologic Neoplasms · China | 1 | UNKNOWN | Aug 2024 | 137 |
How it is read
Names in the registry
- “TQB3702 tablets”, 3 entries
- “TQB3702 Tablets”, 1 entry
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 2 studies
- Hematologic Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.